NERVGEN PHARMA CORP.

NervGen reports from the phase‑1b/2a CONNECT SCI study that biomechanical analyses for NVG‑291 showed a statistically significant improvement in gait quality (global statistical test p=0.0197; treatment effect +0.45). All ten patients treated with NVG‑291 were classified as responders versus 1 of 10 in the placebo group (p=0.0001); individual measures of coordination, mechanical effort and postural stability also favored NVG‑291. NervGen completed an end‑of‑phase‑2 meeting with the FDA and plans to start the pivotal phase‑3 RESTORE trial in mid‑2026; the company remains unprofitable and the stock recently fell sharply (current price $2.08, market capitalization ~ $218 million). » Altro su de.investing.com

NervGen Pharma set a guaranteed public offering of 24,000,000 common shares at US$2.50 per share and accompanying warrants for up to 24,000,000 additional shares at an exercise price of US$3.68. The offering is expected to raise about US$60 million before costs and is planned to close on May 26, 2026. Proceeds, together with existing funds, are intended to finance development of the drug candidate NVG-291 and general corporate purposes. After the announcement, the stock plunged about 39.7% in premarket trading. » Altro su de.investing.com

NervGen is offering 24 million common shares plus accompanying warrants to purchase up to a further 24 million shares at an issue price of $2.50. Each warrant is exercisable immediately, has an exercise price of $3.68 and expires in five years. Gross proceeds before fees are estimated at about $60.0 million; closing is expected on May 26, 2026. NervGen intends to use the net proceeds to fund clinical trials for NVG‑291 and for general corporate purposes; the company remains unprofitable (loss of $0.40 per share over the last twelve months). » Altro su de.investing.com